Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the breast cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of pharmacy and medical benefits.
Subscribe to:
Post Comments (Atom)
< + > It’s Time for “Actioning Information” to Move Past Interoperability’s Endless Data
The following is a guest article by E ffie Carlson, CEO at Watershed Health The Problem Is Not Only Data Availability, It’s What We Do Wi...
No comments:
Post a Comment